Answers are grounded in this paper and cite their sources.
Purpose Corticosteroid injection is the primary nonsurgical treatment for trigger finger, yet substantial variation exists in corticosteroid type, dosage, injection technique, ultrasound guidance, anesthetic use, and patient selection. This narrative review synthesizes current evidence on these technical and clinical factors and outlines practical recommendations to optimize outcomes. Methods A structured search of MEDLINE, EMBASE, Scopus, and the Cochrane Library identified studies evaluating corticosteroid injection for trigger finger. Eligible publications included randomized trials, prospective and retrospective comparative studies, systematic reviews, and relevant observational studies. Evidence was synthesized qualitatively across domains including corticosteroid type and dose, adjunctive anesthetic use, ultrasound-guided versus blind injection, injection approach and location, outcomes in diabetic patients, repeat injections, and emerging injectable alternatives. Results Corticosteroid injection remains an effective first-line treatment. Triamcinolone and methylprednisolone are the most extensively studied agents, though comparative findings regarding superiority are inconsistent. Among dosing strategies, 20 mg triamcinolone provides the most reliable short-term symptom remission, without evidence of reduced long-term recurrence. Adding local anesthetic does not consistently improve outcomes and offers limited analgesic benefit. Ultrasound guidance may enhance early recovery and procedural accuracy, but long-term results are comparable to those of blind injection. Extra-sheath and intra-sheath injections demonstrate similar efficacy, and neither dorsal nor volar approaches show clear advantage. Diabetes—particularly with poor glycemic control or systemic complications—may reduce treatment success, although recent studies suggest that outcomes depend on multiple patient factors. Repeat injections offer modest benefit but are less effective than the initial injection. Nonsteroidal alternatives such as nonsteroidal anti-inflammatory drugs, hyaluronic acid, and platelet-rich plasma remain investigational. Conclusions Corticosteroid injection remains the first-line treatment for trigger finger. Triamcinolone 20 mg is the preferred first-line agent, extra-sheath injection at the A1 pulley is as effective as intra-sheath injection, and neither the volar nor dorsal approach is superior. Ultrasound guidance and local anesthetics are optional rather than routine. Diabetes and other patient factors influence outcomes, supporting individualized treatment. High-quality comparative studies with standardized outcomes and longer follow-up are needed to refine injection strategies and clarify the role of emerging injectables.
No takes yet. Share an insight, caveat, or question.
Kamrani et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: